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Utilizing standard hybridoma techniques and a neutrophil 
chemotaxis assay for screening we produced a mouse mono-
clonal IgM antibody, 59/4, selected for specific inhibition of 
human neutrophil chemotaxis to the N-formyl-methionyl-
leucyl-phenylalanine peptide (fMLP). Antibody 59/4 inhib-
ited neutrophil chemotaxis to fMLP, but not human C5a or 
leukotriene B4. The antibody exhibited specific homoge-
neous binding to PMNs, heterogeneous binding to mono-
cytes, and did not bind to lymphocytes in a pattern similar to 
~ the profile of N-formyl peptide binding in flow cytometric 
N eutrophils (PMNs) playa pivotal role in inflamma-tion, with many functions resulting from the inter-action of soluble mediators with the PMN membrane. C5a and the formylated peptide, N-formyl-methionyl-Ieucyl-phenylalanine (fMLP). 
are soluble mediators that bind to specific cell-surface receptors and 
stimulate numerous common cellular functions including chemo-
taxis, lysosomal degranulation. phagocytosis. and oxygen .metabo-
lite generation [to -3]. Each of these PMN functio~s contnb~te.s to 
tissue inflammation. C5a and fMLP bmd to specific and dlstmct 
cell-surface receptors [1-3] and elicit similar PMN biologic re-
sponses. The process by which different stimuli effect common 
responses and cellular functions is poorly understood. 
" To further clarify the mechanism of PMN responses to media-
I tors, we produced monoclonal antibodies that bind to PMN mem-
branes and alter a specific cell function. To achieve this goal, we 
screened hybridomas with a PMN chemotaxis assay and selected 
hybridoma products that inhibited chemotaxis to specific chemoat-
tractants. In this study we describe a monoclonal antibody, 59/4, 
that specifically inhibits PMN chemotaxis to fMLP. 
MATERIALS AND METHODS 
Monoclonal Antibodies Additional antibody preparations used in this 
study were obtained from the following sources: Leu M1 (Bect~n-Dickin­
son, Mountain View, CAl, Thy1.2 (New England Nuclear, WIlmmgton, 
DE), and 1B4 (gift of Dr. Michael Frank, NIAID, NIH). 
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Abbreviations: fMLP: N-formyl-methionyl-leucyl-phenylalanine; 
, PMNs: neutrophils. 
analysis. The antibody did not inhibit the binding of fluores-
cein-conjugated fMLPK or fMLeH)p ligands to neutrophils 
in flow cytometric or competitive binding assays. Other neu-
trophil functions including myeloperoxidase release and ro-
sette formation with immunoglobulin or immunoglobulin 
C3b-coated sheep erythrocytes were not affected in the pres-
ence of antibody 59/4. These results suggest that 59/4 spe-
cifically inhibits chemotaxis to fMLP. ] Invest Dermatol 
101:377-382, 1993 
Cell Preparation Human PMNS were prepared from heparinized 
veno~s blo~d (10 units ofheparin/ml of blood) by Ficoll-Hypaque gradient 
centnfugatlOn [4] followed by 5% dextran sedimentation. Red blood cells 
were removed by hypotonic lysis followed by three serial washes with 
Hanks' balanced salt solution (HBSS) without calcium and magnesium 
(Ca++ and Mg++ free HBSS; Biofluids. Rockville. MD). Final suspensions of 
PMNs were prepared with complete HBSS at designated concentrations for 
various procedures. 
Hybridoma and Antibody Production Eight- to 12-week-old female 
BALBlc mice (Frederick Cancer Research Center. Fort Detrick, MD) were 
immunized with intraperitoneal injections of whole PMNs at a concentra-
tion of 4 X 107 per ml, followed by booster injections at 14 and 21 d. Three 
days follo~ing th.e last i~munization. a sin~le-cell suspension of spleen cells 
from the Immu111zed a111mals was fused With Sp 2/0 myeloma cells in the 
presence of polyethylene glycol as described by Kohler and Milstein [5,6]. 
After 2-3 weeks, 100-tll aliquots of tissue culture supernatants from wells 
exhibiting cell growth were screened for antibodies that inhibited PMN 
chemotaxis to either chemoattractant fMLP (10-7 M) or C5a (10-7 M). 
Viable hybridoma cells that screened positive from the master plate were 
cloned by limitng dilution. 
lmm~noglobulin class o~ hybridoma supernatants was determined by 
double Immunodlffuslol~ With antisera specific to mouse immunoglobulin 
classes and subclasses (BlOproducts, Indianapolis, IN). 
, For characterizatio~ studies, ascites were prepared by intraperitoneal in-
Jection of 1-2 ~ 10 hybndoma cells/ml into prisrane-treated BALB/c 
mIce. ASCites flUId was collected at 14-21 d, centrifuged to remove cellular 
debris. and stored at 4°C with 0.1 % NaN,. In some studies. a 40% ammo-
nium sulphate fraction of ascites was prepared. 
Chemotaxis Assay PMN chemotaxis was quantified with a 48-micro-
well chamber [7,8] that utilized a polyvinylpyrrolidone-free polycarbonate 
filter (Nuclepore Corp., Pleasanton, CAl. Neutrophils were suspended in 
complete HBSS at a concentration of 1 X 106/ ml for this assay. For screen-
ing hybridoma supernatants and antibody preparations, a cell suspension of 
2 X 106/ml was mixed with an equal volume of antibody. Random migra-
tion was measured by determining cell migration to medium alone; directed 
migration by determining cell migration to either 10-7 M concentrations of 
fMLP (Sigma Chemical, St. Louis, MO) or human C5a (gift of Dr. 
0022-202X/93/S06.00 Copyright © 1993 by The Sociery for Investigative Dermatology, Inc. 
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K. B. Yancey, U.S.H.S.). Some experiments were performed using leuko-
triene B. as the chemoattractant (LTB.; Sigma). The migrated cells were 
counted with an Optomax System [V [mage analyzer (Optomax, [nc., 
Hollis, NH). The results were expressed as the mean ± SD of triplicate 
assays and represent the total number of migrating cells per square milli-
meter of filter surface. 
For screening of hybridoma supernatants from the master plate and limit-
ing dilutions, clones were selected that exhibited a 50% or greater inhibition 
of directed migration of neutrophils to either chemoattractants fMLP or 
C5a. The formula for determining inhibition values is as follows: 
(number of cells migrated + antibody) 
- number of cells migrated random X 100 
(number of cells migrated - antibody) . 
- number of cells migrated random 
1-
Flow Cytometry Purified PMNs (2 X 106/ml) in phosphate-buffered 
saline (PBS; Biofluids, Rockville, MD) were preincubated with equal al i-
quots of ammonium sulphate fractions of hybridoma ascites (59/4) or con-
trol ascites (Sp 2/0). The mixture was incubated on ice at 4·C for 30 min 
followed by triplicate washes with PBS. Cells were then incubated with a 
1 : 10 dilution of phycoerythrin-conjugated goat anti-mouse kappa antibody 
(Becton Dickinson) for an additional 30 min. Following triplicate washing 
with PBS, ce lls were suspended in 1 ml PBS and analyzed with an Ortho 
Spectrum III flow cytometer equipped with an argon laser and a model 2140 
computer (Ortho Diagnostics Systems, Westwood, MA). Analyses were 
performed using logarithmic scale of fluorescence intensities. 
Experiments were performed to determine whether the antibody prepara-
tions blocked the binding of fluorescein-conjugated N-formyl-methionyl-
leucyl-phenylalanine-Iysine (fMLPK-FI; gift of Dr. Robert Aksamit, 
NIMH, ADAMHA). PMNs were prcincubated with antibody preparations 
for 15 - 30 min at 4· C and washed with PBS. The cells were then incubated 
at 4·C for 15 min with various concentrations of fMLPK-Fl. The specifi-
city of binding was determined in replicate samples containing a thousand-
fold excess of non-fluorescent fMLPK. Following serial washes with PBS, 
flow cytometric analyses of the samples were performed. The results are 
expressed as the change in mean channel fluorescence of specific fMLPK-FI 
binding. 
Radioligand Binding Assay FML(3H]P radio ligand binding assays were 
performed as previously described [9]. One hundred-microliter aliquots 
containing 1 X 106 PMNs were preincubated with equal amounts of anti-
body ascites (59/4 or Sp 2/0) for 30 min before initiation of binding assay. 
Various concentrations of fML(3H]P (specific activity 46.4 cijmmol; New 
England Nuclear, Boston, MA) with or without excess labeled ligand were 
then incubated with the antibody-treated and control cell samples in a final 
reaction volume of250 Ill. The total, specific, and nonspecific binding were 
determined; results were expressed as fMLP[3H)P specific binding. 
Erythrocyte Rosette Assays PMNs wete suspended at a concentration 
of 2 X 106/ml in RPMI 1640 medium (Gibco, Grand Island, NY) and 
incubated with 1 mM phenylmethylsulfonyl fluoride (PMSF; Sigma) at 
37·C for 30 min. Aliquots of cells (100 Ill) were then incubated with various 
di lutions of untreated sheep erythrocytes (E), immunoglobulin-coated 
etythrocytes (E-[gG), or complement-coated erythrocytes (EAC3b and 
EAC3bi). The cell mixture was centrifuged at 400 rpm for 5 min at room 
temperature. The samples were incubated at 37"C for 30 min on a rotating 
platform in a moist chamber with 5% CO2, The samples were placed on ice 
and gently mixed; 20-111 aliquots of each sample were then scored for roset-
ting. At least three erythrocytes adherent to the cel l surface were necessary 
for the identification of a rosette, and at least 200 target cells were counted 
for each sample. 
Myeloperoxidase Release Assay PMNs were suspended in HDSS at a 
concentration of 8 X 106/ml and pretreated at room temperature for 5 min 
with cytochalasin B (5 J.lg/ml). Twenty-five -microliter aliquots of cells 
were added to serial dilutions of ascites fluid (59/4 or Thy-l.2) in HBSS and 
incubated for 30 min at 37·C. Then, 10-.u1 aliquots of a 10- 6 M solution of 
fMLP were added to each well and incubated at room temperature for 
10 min. Mycloperoxidase release was measured colore metrically by the 
methods and assay described by W ebster and Henson (10]. Total myeloper-
oxidase activity was determined by adding 1 % Triton X to a control well 
containing unstimulated cells and reagents. The percent inhibiton of myelo-
peroxidase release was calculated as fo llows: 
OD 490 mm cells + antibody 
1 - X 100, 
OD 490 mm cells - antibody 
where OD is optical density. 
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Radiolabeling, Immunoprecipitation, and Polyacrylamide Gel 
Electrophoresis Radiolabeling using 12S [ was performed as described by 
Skubitz et a/ [11). lnununoprecipitation using radiolabeled neutrophils was 
performed as described [11] with the following modifications. 
Preclearing steps consisted of mixing the radiolabeled cell extract (ap-
proximately 2 X 107 cpm) with 200 III of control mouse ascites to a final 
volume of 1.25 ml in 20 mM Tris HCI pH 7.6, 150 mM NaCI, 0.5% 
NP-40, 0.02% NaN3, 2 mM PMSF, and 0.5 mg/ml gelatin. The mixture 
was incubated at 4· C for 1 h and subsequently added to 1 ml of washed 10% 
Staphylococcus protein A (SPA, Pansorbin; Calbiochem, LaJolla, CAl. After 
30 min incubation at 4 · C, the suspension was centrifuged at 4000 rpm for 
10 min; the supernatant was collected and then mixed with another 1-ml 
aliquot of washed SPA. The procedure was repeated three times. 
After preclearing, immunoprecipitation of labeled cellular proteins was 
achieved by mixing aliquots of cell extract with 100 III of antibody 59/4 or 
Thy1.2 in 20 mM Tris HCI pH 8.2, 100 mM NaCl, 0.5% NP-40, 1 mM 
ethylenediaminetetraacedic acid (EDTA) 2 mM phenylmethylsulfonyl flu-
oride, and 0.5 mg/ml (final concentration) gelatin. Following incubation at 
4 · C overnight, 25 .ul of anti-mouse IgM antiserum (Litton Dionetics, Ken-
sington, MD) was added and the mixture was incubated at O·C for 1 h. Five 
hundred microliters of washed 10% SPA was added and followed by an 
incubation for 30 min at 4·C. After centrifugation at 2500 rpm for 10 min, 
the pellet was washed twice with buffer containing 20 mM Tris HCI, pH 
8.2,1 mMEDTA,100mMNaCI , O.5% NP-40,2.5M KCI,and2.5 mg/ml 
gelatin. The pellet was suspended in Laemmli buffer (62 mM Tris HCI, ph 
6.8,2% sodium dodecylsulphate, 10% glycerol, 5% 2-mercaptoethanol, and 
0.001 % bromophenol blue), incubated at 100·C for 2 min, then centrifuged 
at 13,700 Xg for 10 min at 4·C. 
The supernatant was analyzed by sodium dodecyl sulphate polyacrylam-
ide gel electrophoresis [12) . Electrophoresis was performed using the 
Laemmli buffer system, appropriate molecular weight standards (BioRad, 
Richmond, CAl, a 3% acrylamide stacking gel, and either 5 - 10% or 5-
15% gradient acry lamide slab gels at a constant 30 mA current. Gels were 
dried, stained, and examined by autoradiography with X-Omat AR diagnos-
tic film. 
Western Blots of Neutrophil Membrane Preparations Membranes 
were isolated from nitrogen-cavitated PMN preparations [13) by centrifuga-
tion over a discontinous sucrose density gradient as described by Caldwell et 
a/ [14]. The membrane fraction was analyzed by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis using the Laemmli buffer system [1 2). 
Gels composed of a 4% acrylamide stacker gel and 10% acrylamide resolving 
gel were run for 1.5 h at a constant current of 40 mAo Western blots of the 
gels were performed using modifications of the procedure described by 
Towbin et a/ [1 5). Primary antibodies including antibody 59/4, AHNl.l (a 
CD15 [gM monoclonal antibody from Dr. Keith Skubitz [11)), and Thy1.2, 
were evaluated over a 1: 5 - 1 : 500 dilution range. 
RESULTS 
Hybridoma Production and Screening The fusion procedure 
resulted in production of 165 primary cultures whose supernatants 
were screened for inhibition ofPMN chemotaxis to 10 -7 M C5a or 
fMLP. Only primary cultures were selected that inhibited chemo-
taxis by 50% or greater compared to control values. After limiting 
dilutions and repeat screenings were performed, eight immuno-
globulin-producing clones were identified: two clones with anti-
bodies that inhibited neutrophil chemotaxis to both chemoattrac-
tants fMLP and C5a, and six clones with antibodies that inhibited 
chemotaxis to only fMLP . All antibodies were mouse IgM immu-
noglobulin class as determined by double immunodiffusion. The 
antibody from a clone identified as 59/4 was selected for further 
characterization because it exhibited the greatest specific inhibitory 
activity of fMLP-stimulated PMN chemotaxis. 
Inhibitory Activity of Antibody 59/4 Various preparations of 
59/4 were tested simultaneously with different cell donors to ex-
amine the reproducibility of this antibody's inhibitory effect on 
c.hemotaxis. Preincubation of .human neutrophils with aliquots of 
tissue culture supernatants, aSCites, or ammonium sulphate fractions 
from hybridoma clone 59/4 consistently inhibited chemotaxis to 
fMLP 60-80% as compared to control values (Fig lA). Cells 
treated with supernatant or ascites from the parent myeloma cell 
line, Sp2/0, did not inhibit chemotactic activity to the chemoattrac-
tant fMLP (data not shown). 
The inhibitory activity of 59/4 on neutrophil chemotaxis was 
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Figure 1. A) Comparison of tissue culture supernatant, ascites fluid , or 
ammonium sulphate fraction preparatIOns of antibody 59/4 for consistent 
inhibition of neutrophi l chemotaxis to to- 7 M fMLP. Each representative 
experiment utilized different neutrophil donors. B) Comparison of antibody 
59/4 and other murine monoclonal IgM antib~dies (Thy 1:2, CD-1S) for 
inhibitory effect on fMLP-stlmulated neutropllli chemotaxIs. Expenments 
were performed four times with different neutrophil donors. 
compared with different mouse IgM monoclonal antibodi~s to ver-
ify the specificity o~ this effect. Pretreatme~1t of P~Ns with 59! 4 
inhibited chemotaxIs to fMLP, whereas prelllcubation of cells with 
Thy 1.2 or Leu Ml did not inhibit chemotaxis. (Fig IB). Two IgM 
monoclonal antibodies were evaluated as control reagents. Thy 1.2 
antibody was included as an irrelevant mouse IgM control, and Leu 
Ml, a CD-15 mouse monoclonal IgM, was included as a control 
because it binds uniformly to human PMNs. Neither of the control 
antibodies inhibited PMN chemotaxis when compared with equiv-
alent concentrations of antibody 59/4. This effect was examined 
using ascites and ammonium sulphate fractions of 59/4 and Thy 1.2 
antibodies and 1 : 10 to 1: 100 dilutions of the commercial CD-15 
antibody preparation. 
Antibody 59/4 inhibited PMN chemotaxis over the chemotactic 
concentration range of to-8 M to 10-6 M (Fig 2B). In contrast, 
antibody 59/4 did not inhibit PMN chemotaxis to any concentra-
tion of L TB. (Fig 2B). Antibody 59/4 did not inhibit chemotaxis to 
C5a (data not shown). These results demonstrate that antibody 59/ 
4 has a selective inhibitory effect on PMN chemotaxis to fMLP. 
Flow Cytometry The pattern and distribution of 59/4 antibody 
binding to human leukocyte populations was examined using flow 
cytometry. Neutrophils stained with 59/4 showed a unimodal shift 
in fluorescence (Fig 3A), suggesting uniform binding of the anti-
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Figure 2. A,B) Dose response of human neutrophil migration in the pres-
ence and absence of antibody S9/4 to molar concentrations of fMLP and 
leukotriene B •. Arrow, random migration values. Data points, means of tripli-
cate values. 
body to the cells. Monocytes stained with 59/4 showed a fluores-
cent intensity shift with the histogram pattern being broader in 
distribution (Fig 3C). Lymphocyte populations stained with 59/4 
did not demonstrate a shift in fluorescence intensity and were iden-
tical to lymphocytes incubated with control ascites (Fig 3E). 
The flow cytometric pattern of 59/4 binding to these leukocyte 
populations is similar to the binding profile of fluorescein-conju-
gated fMLPK. fMLPK-FI bound uniformly to PMNs as demon-
strated by a unimodal shift in fluorescence intensity of the labeled 
c.ell population (Fig ~B). ~onocytes ~xhibited a ~imodaJ distribu-
tion of fluorescence Illtenslty with dlstlllct poslt!ve and negative 
subsets of cells (Fig 3D). FMLPK-FI did not bind to lymphocytes; 
lymphocyte fluorescence was identical to control reagent fluores-
cence (Fig 3F). 
Effects of 59/4 on N-formyl Peptide Binding to Human 
PMNs Two binding assays were used to examine the effect of 
59/4 on N-formyl peptide binding to PMNs. Pretreatment of 
P.M~s with 59/4 or control ascites, Sp2/0, did not alter the specific 
bllldlllg profile of fMLPK-FI (Fig 4A). Identical concentrations of 
antibody 59/4 used in binding assays inhibited chemotaxis of neu-
trophils to fMLP. 
Antibody 59/4 and control ascites, Sp2/0, were also treated for 
their effects on FML[3H]P binding to PMNs. Neither 59/4 nor 
Sp2/0 inhibited the specific binding of FML[3HJP to PMNs when 
tested over a concentration range of to- IO M _10- 7 M (Fig 4B). 
Rosette Formation Antibody 59/4 and an irrelevant control 
mouse IgM antibody, Thy1.2, were compared for their effects on 
the ability ofPMNs to form rosettes with either antibody-coated or 
antibody-complement-coated sheep erythrocytes. PMNs preincu-
bated with various concentrations of 59/4 or Thy1.2 did not alter 
the percentage of cells rosetting with E-IgG, EAC3b, or EAC3bi 
(Table I). In contrast, pretreatment of PMNs with 1B4 [16], an 
antibody directed to the CR 1 receptor that avidly binds C3b, signif-
icantly altered the percentage of cells rosetting with EAC3b. 
380 McNEELY ET AL 
Neutrophils 
A B 
Monocytes 
Q; C 
o 
.0 
E 
::J 
Z 
Gi 
u 
CD 
> 
~ 
Gi 
a: 
Lymphocytes 
E F 
Relative Fluorescence Intensity 
Figure 3. Flow cytometric analysis of binding of antibody 59/4 to neutro-
phil (A) , monocyte (e), and lymphocyte cell populations (E) in comparison 
with the binding profile of fluorescein-conjugated fMLPK to similar cell 
populations (B, D, F). Non-shaded figures, control cell populations. 
Myeloperoxidase Release Myeloperoxidase release from 
fMLP-stimulated PMNs measured in the presence or absence of 
antibody. The fMLP-stimulated release of myeloperoxidase was in-
hibited approximately 50% when PMNs were pretreated with 59/4 
(Fig 5). This inhibitory effect of 59/4, however, was nonspecific 
because similar protein concentrations of an irrelevant IgM anti-
body (Thy 1.2) produceds a similar effect (Fig 5) . 
Immunoprecipitation and Western Blotting Several experi-
ments were performed to determine whether antibody 59/4 immu-
noprecipitated detectable neutrophil antigens. In all of the experi-
ments, 59/4 did not identify neutrophil antigens that were different 
from the control antibody Thyl.2 or normal mouse serum. In addi-
tion, 59/4 did not detect any changes when evaluated in Western 
blots. 
DISCUSSION 
This study describes the production and characterization of a mur-
ine IgM monoclonal antibody, 59/4, which binds to human neu-
trophils and inhibits chemotaxis to fMLP. Hybridomas were 
screened with a chemotaxis assay using two different chemoattrac-
tants, C5a and fMLP. Clones that selectively inhibited chemotaxis 
to only one chemoattractant were chosen from the screening assay. 
The specificity of antibody 59/4 was confirmed in comparative 
studies with the murine IgM monoclonal antibodies CD15 and Thy 
1.2. Neither the CD15 antibody, which binds to human PMNs, nor 
the Thy1.2 antibody, which does not bind to PMNs, inhibited 
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Figure 4. A) Flow-cytometric binding study of fluorescein-conjugated 
fMLPK to human neutrophils in the presence of antibody 59/4. N eutrophils 
were pretreated with antibody 59/4 ascites (6), control ascites (0), or phos-
phate-buffered saline ~) and various concentrations of fLMPK-FI. Data 
expressed as change in mean channel fluorescense intensity . B) Competitive 
binding study of fML[3H]P to neutrophils in the presence of antibody 59/4. 
Neutrophils preincubated with PBS ~), control ascites (0). or antibody 
59/4 (6) were suspended in buffer containing various concentrations of 
tritiated and cold ligand. Results are expressed as counts specifically bound to 
neutrophils. 
neutrophil chemotaxis to fMLP. Antibody 59/4 specifically inhib-
ited neutrophil chemotaxis to fMLP and did not affect chemotaxis 
to C5a or L TB4 • These findings indicate that the antibody does not 
alter chemotactic activity by a nonspecific effect on neutrophil ad-
herence. 
Flow cytometric analysis of 59/4 binding to human leukocyte 
revealed that the antibody bound to PMNs and monocytes but not 
to lymphocytes . The binding profile of the antibody was strikingly 
similar to the binding of fluorescent fMLPK, suggesting that the 
Table I. Effect of Antibody Pretreatment on Neutrophil 
Rosette Formation 
Antibody E-IgG EAC3b EAC3bi 
Thy 1.2 
1:10 57% 78% 51 % 
1:100 50% 86% 52% 
59/ 4 
1:10 51% 80% 58% 
1:100 56% 85% 52% 
IB4 Not done 4% 50% 
No antibody 57% 85% 52% 
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Figure 5. MyeioperOlcidase release of fMLP-stimulated neutrophils in the 
presence of antibody 59/4 or control monoclonal IgM antibody Thy 1.2. 
antigen for antibody 59/4 may ?e associated with the N-formyl 
peptide receptor. Flow cytometnc and radlOhgand b1l1d1l1g assays 
were performed to determine whether antibody 59/4 inhibited the 
binding of fluorescent fMLPK or radiolabeled fML[3H]P to PMNs. 
and it was found that the antibody did not inhibit the binding of the 
N-formyl peptide ligands to PMNs. These results demonstrate that 
the ligand-specific inhibitory effects of antibody 59/4 are not due to 
an inhibition ofN-formyl peptide binding to PMN receptors. 
Studies performed to determine whether antibody 59/4 inhibited 
other PMN functions demonstrated that the antibody did not alter 
rosette formation with IgG-. C3b-. or C3bi-coated sheep erythro-
cytes nor did it specifically inhibit myeloperoxidase release of 
fMLP-stimulated PMNs. Antibody 59/4 appears to have a selective 
inhibitory effect on PMN chemotaxis to N -formyl peptide. 
Numerous monoclonal antibodies that bind to PMNs and sup-
press chemotaxis have been produced. (Table II) . These include 
NCD1 and NCD3 [17.18]. NMS-1 and NMS-7 [19 -21]. antibody 
1-14 [22]. antibody TM316 [23]. antibody 60.3 [24]. and PMN7C3 
[25-27], NCD1 and NCD3, murine monoclonal IgGs, inhibit 
PMN chemotaxis to fMLP. NCDI also inhibits chemotaxis to C5a 
and inhibits lysosomal enzyme release [17] , whereas NCD3 only 
partially suppresses PMN chemotaxis to C5a and does not affect 
lysosomal enzyme release [18]. NMS-l and NMS-7, murine mono-
clonal IgM and IgG isotypes, respectively, inhibit PMN chemotaxis 
to N-formyl peptides [19,20] . NMS-l also inhibits chemotaxis to 
C5a [21] . Both NMS-l and NMS-7 enhance lysosomal enzyme 
release and NMS-l increases N -formyl peptide-mediated oxidative 
burst activity in neutrophil s. Antibody 1-14, a murine monoclonal 
IgG, partially inhibits PMN chemotaxis to fMLP and inhibits su-
peroxide production and rosetting of complement-coated sheep 
erythrocytes [22]. In contrast, antibody 1-14 increases PMN adher-
ence and fMLP-stimulated lysosomal enzyme release. TM316. a 
murine IgM monoclonal antibody, inhibits neutrophil chemotaxis 
to fMLP, activated serum, and a lymphocyte-derived chemotactic 
factor; however, presence of this antibody does not affect rosette 
formation of complement or IgG-coated erythrocytes, chemilu-
munesce. or superoxide anion production [23]. Antibody 60.3, a 
murine monoclonal IgG2a, reacts with a cell-surface antigen ex-
pressed on all peripheral blood lymphocytes, monocytes, and 
PMNs, and on more than 90% of bone marrow mononuclear cells. 
Antibody 60.3 inhibits PMN chemotaxis to fMLP and blocks the 
lytic activity of cytotoxic T lymphocytes and natural killer cells 
[24]. 
The PMN-specific antibody PMN7C3 is a murine monoclonal 
IgG3 that was initially described for its inhibitory effects on oxida-
tive metabolism triggered by serum-opsonized zymosan or Cat/dida 
albical1s [25]. PMN7C3 does not affect superoxide release in PMN 
stimulated with IgG-opsonized particles or fMLP. The antibody 
inhibits PMN chemotaxis to N-formyl peptide and zymosan-acti-
vated serum; however, it stimulates shape changes, leukoagglutina-
tion, and chemokinesis [26] . PMN7C3 recognizes glycoproteins 
bearing the oligosaccharide lacto-N-fucopentaose III, which in-
clude LFA-l , p150,95, the C3bi receptor on neutrophil plasma 
n1.embranes, and a group of granule-associated glycoprotei ns [27]. 
PMN7C3 is reported to be a member of the cluster of differentia-
tion (CD) 15 cluster as defined by the Third International Work-
shop on Human Leukocyte Antigens because it reacts with lacto-N-
fucopentaose III [11] . CD15 antibodies have diverse effects on 
PMN function [11] ; however, most CD15 antibodies do not inhibit 
PMN chemotaxis [28] . 
Antibodies to common acute lymphoblastic leukemia antigen 
(CALLA/COlO) and leukocyte common antigen (LCA/CD45) 
have inhibitory effects on PMN chemotaxis [29 ,30]. Antibodies to 
CALLA/COlO, a nonintegra l 100-kD membrane glycoprotein 
that is expressed on a variety of normal and tumor cells, partially 
1I1lublt PMN chemotaxis (:520%) to FMLP and C5a without af-
fecting degranulation or aggregation to these stimuli [29]. Antibod-
ies to selected epitopes of LCA/CD45, a fami ly of h igh -
molecular-weight glycoproteins that are expressed on all leukocyte 
plasma membranes, significantly inhibit human PMN chemotaxis 
to L TB4 and C5a, minimally inhibit chemotaxis to FMLP, and have 
Table II. Summary: Monoclonal Antibodies that Inhibit N eutrophil Chemotaxis to N-formyl Peptide 
Monoclonal Chemotaxis 
Antibody C5a Formyl Pep 
59/4 0 ! 
1-14 NRb ! 
60.3 NR ! 
CALLA/CD to !, !, 
LCA/CD45 ! !, 
NCD 1 ! ! 
NCD3 !, ! 
NMS-1 ! ! 
NMS-7 NR ! 
PMN7C3 ! ! 
TM316 NR ! 
• EC. complement-coated sheep erythrocytes. 
, NR. not reported; 0, no effect; ~ . decreased; t. increased. 
' Partial inllibition of chemotaxis (i.e., :520%) was reported. 
EC' 
LTD. Dinding 
0 0 
NR ! 
NR NR 
NR NR 
! NR 
NR 0 
0 0 
NR NR 
NR NR 
NR ! 
NR 0 
J Antibody recognizes glycoproteins bearing the oligosaccharide lacto-N-fucopentaosc III. 
Metabolic Activation 
by Formyl Pep Antigen References 
o Degranulation NR 
! 0 2' generation 94 kD [22] 
i Degranulation 
NR 94, 130, 150 kD [24] 
o Degranulation 95 - 100kD [28] 
o 0 2' generation 180 kD [29] 
o 0 2' generation NR [1 7] 
! Degranulation 
o 0 2' generation NR [18] 
o Degranulation 
i 0 2' generation 70, 95. 140. 170 kD [1 9] 
i Degranulation 
o 02' generation NR [20] 
i Degranulation 
o 0 2' generation CD15J [25-27] 
o 0 2' generation 78 kD [23J 
o Chemiluminescence 
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no effect on PMN chemotaxis to neutrophil-activating protein-l 
(NAP-1/IL8 [30]). LCA/CD45 antibodies that inhibit chemotaxis 
do not affect PMN superoxide responses to the chemoattractants. 
These findings suggest that certain PMN LCA/CD45 epitopes may 
interact with L TB4 and C5a receptor-associated molecules and reg-
ulate chemotactic responses. CALLA/CD10 and LCA/CD45 epi-
topes appear to playa role in chemotaxis events that are distal to 
receptor-ligand binding. 
Monoclonal antibodies provide specific probes for dissecting 
neutrophil-activation events. The ability of monoclonal antibodies 
to block selected events during activation without affecting other 
events elicited by a common stimulus indicate that neutrophil acti-
vation pathways are divergent. Antibody 5914 described in the 
present study appears unique because its inhibitory effect is targeted 
at the chemotactic response to a specific chemoattractant, N-formyl 
peptide. This antibody's characterization is unlike studies of other 
monoclonal antibodies summarized in Table II that inhibit neutro-
phil chemotaxis, because we evaluated the effects on several distinct 
chemoattractants and examined othe~ functi?nal re.sp~nses includ-
ing degranulatIOn and rosette fonnatlon . Thls speclficlty lS a result 
of the approach taken in this study, in which clones were screened 
with chemotaxis assays using rwo different chemoattractant stimuli 
as screening reagents. Because antibody 5914 binding to neutrophils 
does not alter the binding of N-formyl peptide, it appears that the 
inhibitory effect of this antibody may occur either on a portion of 
the receptor other than the ligand-binding site or on a receptor-as-
sociated molecule involved in chemotactic activation. Further char-
acterization of antibody 5914 binding specificity, antigen expres-
sion, and distribution in fMLP-stimulated PMN may provide useful 
information about chemotactic mechanisms. 
We gratefu lly acknowledge Dr. Kristina N. Prodouz for performing Westem blot 
" "alyses. 
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